Why Is Axon (AXON) Down 14.3% Since Last Earnings Report?

Axon (AXON) reported strong second-quarter 2025 results, with adjusted EPS of $2.12 and revenues of $668.5 million, both significantly surpassing consensus estimates, driven by robust demand for devices and growth in premium software solutions. The company also raised its full-year 2025 revenue guidance to $2.65-$2.73 billion. Despite this operational outperformance, AXON shares have declined 14.3% since the report, underperforming the S&P 500, a trend potentially influenced by negative adjusted free cash flow in the first half of 2025 and recent downward revisions in analyst estimates.

Analysis

Axon Enterprise (AXON) presents a conflicting narrative for investors, where strong operational performance is being overshadowed by underlying financial concerns. The company delivered a significant second-quarter 2025 earnings and revenue beat, with adjusted EPS of $2.12 surpassing estimates by 37% and revenue growing 33% year-over-year to $668.5 million. This growth was fueled by robust demand for its TASER 10 and Axon Body 4 products, and notably, a 38.8% revenue surge in its high-margin Software & Services segment, which saw its adjusted gross margin expand to 78.9%. Despite this top-line strength and a subsequent raise in full-year 2025 revenue guidance, the stock has fallen 14.3% since the report. This negative market reaction appears driven by deteriorating cash flow metrics and rising costs. Specifically, adjusted free cash flow was negative $113.7 million for the first half of 2025, a sharp reversal from a positive $39.3 million in the prior-year period. Furthermore, total operating expenses climbed 48.6%, outpacing revenue growth. The situation is compounded by post-earnings analyst sentiment, as consensus estimates have been revised downward by 25%, signaling that the market is discounting the strong headline results in favor of focusing on cash generation and expense management.

Key Decisions for Investors

• Investors should weigh Axon's robust revenue growth and raised guidance against the significant deterioration in free cash flow and a 48.6% increase in operating expenses, as the market is clearly prioritizing profitability and cash generation over top-line momentum.
• Monitor upcoming earnings for any improvement in free cash flow and operating margins, as a continuation of the negative cash flow trend could exert further downward pressure on the stock despite strong product demand.
• Note the sharp divergence between the company's positive operational report and the subsequent 25% downward revision in analyst consensus estimates; this suggests that while the long-term growth story may be intact, near-term profitability concerns warrant caution.
• Given the stock's 'A' momentum score but 'F' value score, it may attract short-term traders, but long-term investors should scrutinize the high levels of planned stock-based compensation ($580-$630 million) and capital expenditures ($170-$185 million) for their impact on future shareholder returns.